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Abstract There is consensus that late vitamin K defi­
ciency bleeding (VKDB) should be prevented by vitamin 
K prophylaxis, One single dose of 1 mg vitamin Ki is 
effective if given i.m. or s.c., but not if given orally. 
Repeated oral doses might be as effective as the par­
enteral dose but the optimal dose regimen remains to be 
established. Different oral dose schedules are presently 
used in different countries. In Australia, Germany, The 
Netherlands and Switzerland active surveillance data on 
late VKDB were collected in a similar manner and 
failure rates compared. Identical case definitions were 
used. There were three basic strategies for oral and one 
for parenteral vitamin K prophylaxis for healthy new­
borns in the four countries: (1) daily supplementation of 
low dose vitamin K (25 pig) for breast-fed infants (The 
Netherlands); (2) 3 x 1  mg orally [Australia (January 
1993 -  March 1994) and Germany (December 1992 — 
December 1994)]; (3) 1 mg vitamin K i.m. (Australia 
since March 1994); and (4) 2 x 2  mg vitamin K (new 
mixed micellar preparation) (Switzerland). The re­
spective failure rates per 100,000 live births (including 
cases given all recommended doses and those given in­
complete prophylaxis) were for strategy: (1) 0.2 (0-1.3) 
in The Netherlands; (2) 2.3 (95% Cl 1.6-3.4) in Germany 
and 2.5 (1.1-4.8) in Australia (oral prophylaxis); (3) 
Australia (i.m. prophylaxis) 0 (0-0.9); and (4) 3.6 (0.7-
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10.6) in Switzerland. The failure rates for complete 
prophylaxis only were: strategy (1) 0 (0-0.7) in The 
Netherlands; (2) 1.8 (1.1-2.8) in Germany and 1.5 (0.5-
3.6) in Australia; (3) Australia (i.m.) 0 (0-0.9); and (4)
1.2 (0-6.5) in Switzerland.
Conclusions The Australian data confirm that three 
oral doses of 1 mg vitamin K are less effective than i.m. 
vitamin K prophylaxis. A daily low oral dose of 25 jig 
vitamin Kt following an initial oral dose of 1 mg after 
birth for exclusively breast-fed infants may be as 
effective as parenteral vitamin K prophylaxis. The 
effectiveness of the ‘‘mixed-micellar’’ preparation of 
vitamin Ki needs further study.
Key words Vitamin K • Infancy • Prophylaxis ■ Late 
vitamin K deficiency ■ Bleeding
Abbreviations C l confidence interval • H IV  human 
immunodeficiency virus • VKBD vitamin K deficiency 
bleeding
Introduction
Vitamin K prophylaxis is required for the prevention of 
late vitamin K deficiency bleeding (VKDB), which may 
be fatal or cause serious morbidity. Without prophylaxis 
incidences of 5-7 per 100,000 live births have been re­
ported in Europe [10]. Administration of 1 mg vitamin 
Kj i.m. is safe and effective in preventing late VKDB, 
and has been common practice in the U.S.A. since 1961, 
whereas a single oral dose of vitamin Ki at birth is less 
effective [10].
In 1992, an unexpected association between i.m. vi­
tamin K  prophylaxis in the neonatal period and later 
childhood cancer was reported [7]. Although un­
confirmed, the report caused considerable concern 
worldwide and prompted changes in national prophy­
laxis policies in several countries [5, 6]. In most of these 
countries the use of repeated oral vitamin K was re­
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commended for healthy neonates, reserving i.m. ad­
ministration for ill newborns, in whom oral adminis­
tration is impractical. Different countries, however, 
adopted different regimens. In Germany and Australia 
three oral doses of 1 mg vitamin Kj were recommended 
in 1992 [5]. In the Netherlands a small daily dose of 25 \xg 
is prescribed for breast-fed infants in addition to a 1 mg 
vitamin K dose at birth either orally for healthy neo­
nates or i.m. in those unwell [22]. In Switzerland two 
oral doses of a new mixed-micellar vitamin Ki pre­
paration have been recommended since 1995 [19].
Is repeated oral prophylaxis as effective as i.m. ad­
ministration for the prevention of late onset VKDB? Are 
there differences between oral regimens regarding their 
efficacy? Here we report the results of an active sur­
veillance trial for late onset VKDB which was carried 
o u t in four different countries with three different oral 
prophylaxis schedules.
Methods
In  The Netherlands, Germany, Australia and Switzerland active 
surveillance programmes for VKDB are in operation, using 
methods developed by the British Paediatric Association Surveil­
lance Unit [8], Surveillance is based on monthly report cards sent to 
paediatricians responsible for inpatient care in paediatric hospitals 
by  the national paediatric organisation. A “nothing to report” 
option was included. A response rate of 85-99% was achieved in all 
countries.
The participating countries have agreed on uniform case defi­
nitions [21] to allow for meaningful international comparison. The 
definition for the first step (a postcard mailed to all paediatricians) 
is deliberately open, encouraging the reporting of all infants in 
whom  bleeding may have resulted from VKDB. All notifications 
are  verified by questionnaire, asking for information about the 
infant, vitamin K administration, clinical presentation and la­
boratory data.
Case definition of late onset VKDB: any infant between 8 days 
and  the end of week 12, with spontaneous bruising/bleeding or 
intracranial haemorrhage associated with prolonged prothrombin 
assay, not due to an inherited coagulopathy or disseminated in- 
travascular coagulation.
Confirmed VKDB was diagnosed, when the prothrombin assay 
results were grossly abnormal compared with standards for age 
(Quick values < 15%; international normalised ratio > 4; pro­
throm bin time > 4  x control value) and at least one of the fol­
lowing was present:
1* Platelet count normal or raised and normal fibrinogen and 
absent fibrin degradation products.
2. Prothrombin time returned to normal after vitamin K  admin­
istration.
3, Concentration of PIVKA proteins exceeded normal controls,
Probable VKDB was assumed when the prothrombin and partial 
thromboplastin assay results were abnormal for age, but not as 
grossly as in “confirmed” cases and if at least one of the above 
mentioned items was documented.
Cases were also classified according to the cause of VKDB:
1. Idiopathic cases were defined as cases in whom no factor pre­
disposing to vitamin K deficiency was identified.
2. Secondary cases were those in whom a predisposing cause, ill­
ness or diagnosis was discovered after presentation with 
bleeding.
I n  both idiopathic and secondary cases, vitamin K  prophylaxis can 
b e  said to have failed either through inadequacy or omission. In
other cases already known to have a disease predisposing to vita­
min K deficiency, vitamin K administration was part o f the normal 
disease management. Bleeding in those cases was not a failure of 
prophylaxis, but a failure of management. These are reported se­
parately.
Oral vitamin K prophylaxis was considered complete if all na­
tionally recommended doses had been given at the time of bleeding. 
Oral vitamin K prophylaxis was considered incomplete, if at least 
one oral dose had been given but not all recommended doses for 
age or if an inadequate dose or preparation had been administered. 
The number of oral vitamin K doses given was documented in the 
respective questionnaires. There were no means to estimate, the 
proportions of healthy neonates given complete or incomplete oral 
vitamin K prophylaxis at different ages.
Results
The relevant vitamin K recommendations for different 
time periods and countries together with the periods of 
which active surveillance are shown in Table 1. The 
surveillance data allowed comparisons between the 
Dutch recommendations (25 pig vitamin K/day for 
breast-fed infants + 1 mg vitamin K at birth), three 
oral doses of 1 mg (Australia and Germany) and two 
oral doses of 2 mg vitamin K (mixed micellar pre­
paration), as recommended in Switzerland.
The surveillance data are shown in Table 2. In The 
Netherlands, five confirmed cases of late VKDB were 
reported from October 1992 until December 1994: three 
cases had known predisposing liver disease not properly 
dealt with, and two were idiopathic cases. In the first 
idiopathic case vitamin K prophylaxis was omitted al­
together, and in the second case the postnatal dose was 
not given. Both babies had been entirely breast-fed. 
There were no cases in infants who received the complete 
recommended prophylaxis. One of the idiopathic cases 
had fatal intracranial bleeding.
In Germany 32 infants met the case definition (28 
confirmed and 4 probable cases) in the study period 
from April 1993 to September 1994. One had a predis­
posing disease requiring specific prophylaxis, not ade­
quately dealt with. Seventeen cases had intracranial 
bleeding. The reported incidence of VKDB despite com­
plete prophylaxis according to national recommenda­
tions was relatively high, 1.8 (1.1-2.8) per 100,000 live 
births.
i
In Australia, a similar prophylaxis protocol to that in 
Germany was used from January 1993 to March 1994. 
During this period intramuscular vitamin K |, 1.0 mg, 
was much less commonly used than the oral doses used 
in healthy neonates (Peter Loughnan, personal com­
munication). There were eight cases (seven confirmed/ 
one probable), over this time [15]. Five of these had 
received prophylaxis according to national re­
commendations. Three cases had intracranial bleeding,
t
one died. The failure rates were almost identical to those 
observed in Germany. In March 1994 the national policy 
was reversed to the previously recommended 1 mg i.m. 
at birth. Until May 1995, no cases of VKDB were ob­
served with this regimen. .
Table 1 Recommendations for vitamin K prophylaxis and surveillance periods for late VKDB in different countries
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Country
The Netherlands
Germany
Australia*
Switzerland
Recommended prophylaxis Time period Surveillance data 
available for
i  * i veil babies
,funwell babies":
"well b a b ie s ’: 
"unwell b a b ie s 3:
" well babies’1:
" unwell babies':
all babies:
" well babies”:
i  t unwell bab ies ':
1 mg vitamin K p .o , & 25 i^g daily from 
week 1 to week 13 (breast-fed)
1 mg vitamin K i.m. & 25jug daily 
(breast-fed)
1 mg vitamin K p.o. day 1, 4-10, 28-42
0,1-0,2 mg vitamin K i.m. or s.c. day 1 
& 1 mg vitamin K p.o. day 4-10, 28-42
1 mg vitamin K p.o. day 1, 3-5, 21-28 
0,1 mg vitamin K i.m. day 1 & day 3-5,
21-28 0,1 mg i.m. vitamin K (or 1 mg p.o.)
1 mg vitamin K utl day 1
2 mg mixed-mi cellar preparation p.o. day
1, 4
0,5 mg mixed-mi cellar preparation i.v. 
or i.m., 2 mg MM-preparation p.o, week 4-6
since 1990
December 1992 -  
December 1994
January 1993 -  
March 1994
since March ’94 
since 1995
October 1992 until 
December 1994
April 1993 until 
September 1994
January 1993 -  
March 1994
March 1994 -  May 1995
January 1995 -  
December 1995
Unless otherwise started the cremopher preparation Konakion was used for single oral or i.m, doses
In Switzerland a new mixed-micellar preparation of 
vitamin Ki has been used from January 1995. All heal­
thy neonates should receive 2 mg of vitamin Kj (Ko­
nakion MM) orally on the 1st and 4th day of life. From 
January 1995 to December 1995 four cases of late 
VKDB were reported (three confirmed and one probable 
case); two of the confirmed cases were idiopathic and 
one of them had hepatobiliary disease. One of these 
three infants had received no prophylaxis, and two had 
been given the ‘old’ fat soluble drops (Konakion pre­
paration), The probable case had very low vitamin K 
dependent clotting factors, which returned to normal 
after vitamin K administration. However, vitamin K
deficiency may not have been the cause of the in­
tracranial bleeding because the baby additionally had a 
low platelet count of 14,000/jil, and angiomatosis of the 
choroid plexus. Because of the limited number of chil­
dren studied in Switzerland to date, 95% confidence 
limits of the failure rate are broad: 1.2 (0-6.5).
Discussion
There is good evidence that parenteral vitamin K pro­
phylaxis (1 mg i.m. at birth) can prevent almost all cases
Table 2 Late VKDB in countries with different recommendations for vitamin K prophylaxis
Netherlands Germany Australia Switzerland
Birth population 439,000 1,200,000 325,000
(vitamin K  p.o.)
325,000
(vitamin K i.m.)
83,000
Number of cases 5 32 8 0 4
a. idiopathic cases 2 13 3 0 3
b. secondary cases 0 18 5 0 1
c. predisposing illness 3 1 0 0 0
Total incidence 1.1 2.7 2.5 0 4.7
a+b+c' (95% Cl)2 (0.4-2.7) (1.8-3.8) (1.1-4.8) (0-0.9) (1.3-11.9)
True incidence 0.5 2.6 2.5 0 4.7
a+b (95% Cl)2 (0.1-1.6) (1.8-3.7) (1.1-4.8) (0-0,9) (1.3-11.9)
Prophylaxis
I. omitted 1 2 0 0 1
IL incomplete 1 6 3 0 2 3
III. complete 0 22 5 0 1
IV. not documented 0 1 0 0 0
Prophylaxis failures 1
(95% Cl)2
-  complete 0 1.8 1.5 0 1.2
prophylaxis (0-0.7) (1.1-2.8) (0.5-3.6) (0-0.9) (0-6.5)
-  complete or 0.2 2.3 2.5 0 3.6
incomplete prophylaxis (0-1.3) (1.6-3.4) (1.1-4.8) (0-0.9) (0.7-10.6)
^per 100,000 live births 
Assuming a Poisson distribution
3An older preparation, Konakion oral drops was given instead of ‘'mixed-micellar’5
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o f  late VKDB [10], Data from switch-over studies in one 
country [4], and from the simultaneous use of different 
prophylaxis strategies in three other countries [9, 16, 20] 
show that vitamin K prophylaxis with one oral dose (1- 
3 mg) is less effective than parenteral vitamin K. Re­
peated oral dose schedules have therefore been re­
commended. However, a recent publication from 
Germany suggests that even repeated oral vitamin K 
prophylaxis may not be as effective as the 1 mg dose 
administered i.m. at birth [12].
The Dutch recommendation for daily supplementa­
tion of vitamin K in exclusively breast-fed infants mi­
mics formula-feeding, which prevents late VKDB almost 
completely [11], by providing a daily intake of about 
50 jig vitamin Kj. Daily supplementation already exists 
for vitamin D. A diluted vitamin K preparation was 
marketed as a food supplement in The Netherlands, 
therefore bypassing time-consuming drug licensing 
procedures. Gynaecologists, midwives and general 
practitioners instruct the parents. The incidence of late 
VKDB despite oral prophylaxis (failure incidence) was 0 
(95% Cl 0-0.7) per 100,000 live births. Before vitamin K 
prophylaxis was introduced in 1990, the estimated in­
cidence was 7 per 100,000 (1984-1986) [24]. A recom­
mendation for daily low oral doses therefore appears 
sound.
In Germany and Australia three oral doses of 1 mg 
vitamin Kj had been recommended in 1992. The “ Cre- 
mophor” solution (Konakion) was used for oral vitamin 
K  prophylaxis in both countries. The failure rates were 
almost identical in both countries and were much higher 
than with parenteral vitamin K prophylaxis [9]. Failures 
resulted not only from “non compliance” (forgotten 
repeat doses) but were also observed in children given 
the recommended vitamin K dose. These observations 
prompted a reversal to i.m. vitamin K in Australia, and 
a dose increase to 3 x 2 mg oral vitamin K in Germany. 
The data following the switch over in Australia confirm 
previous observations, that i.m. prophylaxis with 1 mg 
vitamin K can prevent almost all cases of late VKDB [4, 
9, 10, 16, 19].
The new mixed-micellar preparation is well absorbed 
[18], even in children with cholestasis [2]. In Switzerland, 
two of the three reported failures of oral vitamin K 
prophylaxis occurred in children given the Konakion 
preparation. In 1993/94 when two oral doses of 2 mg of 
the old Konakion were recommended in Switzerland, 
the incidence of late VKDB had been about 4.2 per
100,000 [17], Under the assumption that most children 
received the mixed-micellar preparation during 1995 in 
Switzerland it appears possible that the number of fail­
ures will be lower with the use of the new mixed-micellar 
preparation (Konakion MM) although the evidence is 
no t conclusive.
Several potential sources of bias must be considered 
for between country comparisons of prophylaxis failure 
rates for the assessment of the relative efficacy of dif­
ferent regimes for oral vitamin K prophylaxis.
1. Constant and identical baseline incidences (without 
vitamin K prophylaxis) in the respective countries are 
mandatory. These baseline incidences are influenced 
by e.g. the breastfeeding habits and the prevalence of 
cholestatic liver disease in the respective countries. 
Although the baseline incidence was similar in reports 
from The Netherlands [24] and Germany [9, 10] 
corresponding data from Switzerland and Australia 
are lacking.
2. Completeness of ascertainment is an issue in all forms 
of surveillance systems. Even with active surveillance, 
complete ascertainment is unlikely, as shown by at­
tempts to measure the incidence of childhood dia­
betes [3, 23], vertical HIV infections [1], multiple 
births [14] and systemic Haemophilus influenzae in­
fections [13]. The under ascertainment, however, ap­
pears to be in a similar range for most conditions 
within one national surveillance system [1, 14, 23] and 
even between similar active surveillance systems [3, 
23]. M ajor differences in the ascertainment between 
different active surveillance programmes therefore 
appear unlikely and meaningful between country 
comparison seems possible.
3. AH failure rates had to be calculated with all live 
births in the denominator because the exact numbers 
of children eligible for oral vitamin K prophylaxis in 
each country is unknown. The proportions of eligible 
children, however, are likely to be similar, due to the 
similarities of the eligibility criteria.
4. The proportions of children, who received all re­
commended doses for oral vitamin K prophylaxis are 
unknown. It is likely, however, that less than 100% of 
the eligible cases received the recommended prophy­
laxis in all countries. All failure rates therefore are 
likely to be underestimated due to a greater de­
nominator than the true numbers exposed. If the 
same proportions of children failed to receive the 
recommended prophylaxis in each country this would 
not account for bias in the international comparison. 
Bias could be introduced, however, if the proportions 
of children given the recommended doses was differ­
ent between the countries compared.
The contribution of these potential sources of bias for 
the comparison of different oral vitamin K prophylaxis 
schedules is difficult to measure. In terms of proper 
epidemiology these results therefore can only be used to 
generate hypotheses to be tested in randomized con­
trolled trials. Such trials would require about 700,000 
children on standard oral vitamin K prophylaxis (e.g. 
3 x 1  mg: 2 expected cases of VKDB/100,000 live births) 
versus about 700,000 children on an optimal regime (e.g. 
3 x 2  mg mixed micellar preparation or daily doses of 
25 j.ig in breast-fed babies plus 1 mg oral vitamin K at 
birth: 0.01 expected cases of late VKDB per 100,000 
livebirths). It is evident that such a trial is logistically 
extremely difficult and expensive. The size of the clinical 
problem (about 7 relevant bleedings due to VKDB per
100,000 livebirths without any vitamin prophylaxis in
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western countries) will hardly convince grant donating 
bodies even in extremely affluent societies to support 
such a study,
Poor evidence from international comparisons -  as 
presented in this paper -  will therefore remain the only 
basis for decision making on the optimal form of vita­
min K prophylaxis.
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